Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Chemotherapie des Harnblasenkarzinoms

Neuigkeiten 2009

Systemic chemotherapy for bladder cancer

News in 2009

  • 53 Accesses

Zusammenfassung

Dieser Beitrag stellt die Ergebnisse aktueller Studien zur systemischen Chemotherapie des fortgeschrittenen/metastasierten Urothelkarzinoms so wie der neoadjuvanten und adjuvanten systemischen Kombinationschemotherapie des resektablen Harnblasenkarzinoms zusammen. Während über lange Zeit die Therapie mit konventionellen Chemotherapeutika dominierte, sind in den letzten Jahren zunehmend Daten zur Behandlung mit zielgerichteten molekularen Substanzen veröffentlicht worden. In Zukunft wird wie in anderen Tumorentitäten das molekulare „Profiling“ von Patienten zur individualisierten Therapieplanung zu erwarten sein.

Abstract

This review summarizes the results of first-line and second-line systemic chemotherapy for advanced urothelial carcinoma as well as data from adjuvant and neoadjuvant trials for locally advanced bladder cancer. Whereas conventional systemic chemotherapy prevailed for over two decades, targeted therapeutics have been introduced to treat urothelial cancer during recent years. As in other tumor entities, molecular profiling will presumably emerge in the future as a means to tailor individual therapy.

This is a preview of subscription content, log in to check access.

Literatur

  1. 1.

    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 48: 189–199

  2. 2.

    Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48: 202–205

  3. 3.

    Albers P, Siener R, Park S et al (2008) Randomized phase III trial of 2nd line gemcitabine/paclitaxel chemotherapy in patients with advanced bladder cancer: Temporary versus maintenance treatment (German Association of Urologic Oncology (AUO) Trial AB 20/99). J Clin Oncol 26(Suppl): 5030

  4. 4.

    André F, Campone M, Hurvitz SA et al (2008) Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 26(Suppl): 1003

  5. 5.

    Bellmunt Molins J, von der Maase H, Theodore C et al (2008) Randomised phase III trial of vinflunine plus best supportive care vs best supportive care alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium. J Clin Oncol 26(Suppl): 5028

  6. 6.

    Bellmunt J, Cos J, Cleries R et al (2002) Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 20: 673–685

  7. 7.

    Bellmunt J, Delgado FM, George C (2008) Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors. Semin Oncol 35: 34–43

  8. 8.

    Bellmunt J, von der Maase H, Mead GM et al (2007) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC 30987 / Intergroup Study. J Clin Oncol 25:(Suppl): 5030

  9. 9.

    Bonfil RD, Russo DM, Binda MM et al (2002) Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. Urol Oncol 7: 159–166

  10. 10.

    Cognetti F, Ruggeri EM, Felici A et al (2008) Adjuvant chemotherapy with cisplatin + gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy. An Italian multicenter randomised phase III trial. J Clin Oncol 26:(Suppl): 5023

  11. 11.

    Dreicer R, Li H, Cooney MM et al (2008) Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group. Cancer 112: 2671–2675

  12. 12.

    Dreicer R, Li H, Stein MN et al (2008) Phase II trial of sorafenib in advanced carcinoma of the urothelium (E 1804): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 26:(Suppl): 5083

  13. 13.

    Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134

  14. 14.

    Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111

  15. 15.

    Fechner G, Siener R, Reimann M et al (2006) Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 60: 27–31

  16. 16.

    Hautmann RE, Gschwend JE, de Petriconi RC et al (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176: 486–492

  17. 17.

    Hutson TE, Vukelja S, Atienza D et al (2008) Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Invest New Drugs 26: 151–158

  18. 18.

    Krege S, Rembrink V, Borgermann C et al (2001) Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. J Urol 165: 67–71

  19. 19.

    Lehmann J, Retz M, Wiemers C et al (2005) Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol 23: 4963–4974

  20. 20.

    Lin CC, Hsu CH, Huang CY et al (2007) Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study. Anticancer Drugs 18:487–491

  21. 21.

    Matsumoto K, Irie A, Satoh T et al (2007) Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma. Int J Urol 14: 1000–1004

  22. 22.

    Milowsky MI, Tickoo SK, Gallagher DJ et al (2008) HIF and mTOR pathways in invasive urothelial carcinoma: A study with potential therapeutic implications. J Clin Oncol (GU-ASCO) 292

  23. 23.

    Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449–456

  24. 24.

    Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124

  25. 25.

    Osai WE, Ng CS, Pagliaro LC (2008) Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anticancer Drugs 19: 427–429

  26. 26.

    Retz M, Gschwend JE (2009) Medikamentöse Tumortherapie in der Uro-Onkologie. Springer, Berlin Heidelberg New York

  27. 27.

    Sternberg CN, Calabro F, Pizzocaro G et al (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92: 2993–2998

  28. 28.

    Sweeney CJ, Roth BJ, Kabbinavar FF et al (2006) Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 24: 3451–3457

  29. 29.

    Vaishampayan UN, Faulkner JR, Small EJ et al (2005) Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer 104: 1627–1632

  30. 30.

    von der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602–4608

  31. 31.

    Zaghloul MS, Boutrus R, El-Hosieny H et al (2008) A controlled prospective randomized placebo-controlled trial of Zoledronic acid in bony metastatic bladder cancer patients. J Clin Oncol 26:(Suppl): 5033

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: PD Dr. med. Retz ist als Referentin für die Fa. Wyeth und Sanofi-Aventis tätig. Prof. Dr. med. J. Gschwend ist als Referent für die Fa. Novartis, Bayer, Roche und Wyeth tätig. PD Dr. med. Lehmann ist als Referent für die Fa. Lilly tätig gewesen. Trotz des möglichen Interessenkonflikts ist der Beitrag unabhängig und produktneutral.

Author information

Correspondence to PD Dr. M. Retz.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Retz, M., Gschwend, J. & Lehmann, J. Chemotherapie des Harnblasenkarzinoms. Urologe 48, 655–662 (2009). https://doi.org/10.1007/s00120-009-2021-5

Download citation

Schlüsselwörter

  • Harnblasenkarzinom
  • Urothelkarzinom
  • Systemische Chemotherapie
  • Adjuvante Chemotherapie
  • Neoadjuvante Chemotherapie

Keywords

  • Bladder cancer
  • Urothelial carcinoma
  • Systemic chemotherapy
  • Adjuvant chemotherapy
  • Neoadjuvant chemotherapy